{"id":"19c18b0f3594","type":"article","url":"https://hartvaat.nl/2026/03/07/baxdrostat-verlaagt-bloeddruk-significant-bij-resistente-hypertensie/","title":"Baxdrostat verlaagt bloeddruk significant bij resistente hypertensie","title_en":"Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trial","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["aldosteronsynthaseremmers","ambulante-bloeddrukmeting","aprocitentan","bax24-trial","baxdrostat","bloeddrukbehandeling","lorundrostat","precision-trial","resistente-hypertensie","resistente-hypertensie-aldosteronremmers"],"journal":"The Lancet","doi":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02549-8/fulltext","source_url":"https://doi.org/https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02549-8/fulltext","authors":["Michel Azizi","Jenifer M Brown","Jamie P Dwyer","John M Flack","Erica S W Jones","Raisa Kurlyandskaya","Hongjian Li","Filip Birve","Aina S Lihn","Shira Perl","Markus P Schlaich","Hirotaka Shibata","Ji-Guang Wang","Bryan Williams","Bax24 investigators"],"significance":9,"published":"2026-03-12","source_date":"2026-03-07","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/bloeddrukmeting-thuismeting-abpm/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/"],"congress":"","summary_en":"The phase 3 Bax24 trial demonstrated that baxdrostat, an aldosterone synthase inhibitor, significantly reduced 24-hour ambulatory systolic blood pressure compared with placebo in patients with resistant hypertension. The results advance aldosterone synthase inhibition as a promising new drug class for treatment-resistant blood pressure.","created":"2026-07-03T10:32:33Z","updated":"2026-07-03T18:39:27Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"In de fase 3 Bax24-trial verlaagde baxdrostat, een aldosteronsynthaseremmer, de 24-uurs ambulante systolische bloeddruk significant vergeleken met placebo bij patiënten met resistente hypertensie. Dit biedt nieuw bewijs voor aldosteronsynthaseremming als behandeloptie voor moeilijk te controleren hypertensie.","abstract_original":"Baxdrostat significantly reduced 24 h ambulatory SBP versus placebo in patients with resistant hypertension, providing further evidence of the potential of aldosterone synthase inhibition for treatment of hard-to-control hypertension."}